Palvella Therapeutics, Inc. (PVLA) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.3M | 19.52M |
| Revenue Growth % | - | - | - | - | - | -100% | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 739K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | 3.79% |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.3M | 18.78M |
| Gross Margin % | - | - | - | - | - | - | - | - | 100% | 96.21% |
| Gross Profit Growth % | - | - | - | - | - | -100% | - | - | - | - |
| Operating Expenses | 14.86M | 11.3M | 10.18M | 9.25M | 7.87M | 4.37M | 2.91M | 1.76M | 6.78M | 15.7M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | 522.02% | 80.4% |
| Selling, General & Admin | 5.52M | 4.18M | 3.65M | 4.13M | 3.8M | 1.82M | 1.47M | 775K | 2.33M | 6.1M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | 179.14% | 31.25% |
| Research & Development | 9.33M | 7.12M | 6.53M | 5.12M | 4.07M | 2.54M | 1.44M | 984K | 4.45M | 9.6M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | 342.88% | 49.15% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -14.86M | -11.3M | -10.18M | -9.25M | -7.87M | -4.37M | -2.91M | -1.76M | -5.48M | 3.09M |
| Operating Margin % | - | - | - | - | - | - | - | - | -422.02% | 15.81% |
| Operating Income Growth % | -88.73% | -158.91% | - | -218.09% | -347.47% | 20.36% | - | - | - | - |
| EBITDA | -14.86M | -10.97M | 0 | -8.12M | -6.97M | -4.37M | -3.12M | -1.73M | -4.58M | 3.83M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | -352.89% | 19.6% |
| EBITDA Growth % | -113.13% | -151.37% | - | -160.58% | -302.66% | 4.76% | - | - | - | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 10.18M | 0 | 0 | 0 | 0 | 0 | 0 | 739K |
| EBIT | -14.86M | -10.97M | -9.84M | -8.12M | -6.97M | -4.37M | -3.12M | -1.73M | -4.58M | -10.75M |
| Net Interest Income | 2.04M | -1.22M | -882K | -664K | -463K | -1.3M | -1.06M | -719K | 455K | 549K |
| Interest Income | 0 | 520K | 628K | 690K | 752K | 0 | 0 | 86K | 455K | 549K |
| Interest Expense | -2.04M | 1.74M | 1.51M | 1.35M | 1.22M | 1.3M | 1.06M | 805K | 0 | 0 |
| Other Income/Expense | -912K | -1.41M | -1.17M | -221K | -314K | 415K | -1.26M | -777K | 898K | -13.84M |
| Pretax Income | -15.77M | -12.71M | -11.35M | -9.47M | -8.19M | -3.95M | -4.17M | -2.54M | -4.58M | -10.75M |
| Pretax Margin % | - | - | - | - | - | - | - | - | -352.89% | -55.08% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -15.77M | -12.71M | -11.35M | -9.47M | -8.19M | -3.95M | -4.17M | -2.54M | -4.58M | -10.75M |
| Net Margin % | - | - | - | - | - | - | - | - | -352.89% | -55.08% |
| Net Income Growth % | -92.63% | -221.79% | - | -127.01% | -222.75% | 13.81% | - | - | - | - |
| Net Income (Continuing) | -15.77M | -12.71M | -11.35M | -9.47M | -8.19M | -3.95M | -4.17M | -2.54M | -4.58M | -10.75M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.20 | -1.08 | -1.03 | -0.86 | -3.68 | -0.88 | -3.37 | -2.00 | -3.71 | -8.70 |
| EPS Growth % | 67.39% | -22.73% | - | 74.48% | -84% | 76.28% | - | - | - | - |
| EPS (Basic) | -1.20 | -1.08 | -1.03 | -0.86 | -3.68 | -0.88 | -3.37 | -2.00 | -3.71 | -8.70 |
| Diluted Shares Outstanding | 13.09M | 11.25M | 11.06M | 11.05M | 2.23M | 2.23M | 1.29M | 1.27M | 1.24M | 1.24M |
| Basic Shares Outstanding | 13.09M | 11.25M | 11.06M | 11.05M | 2.23M | 2.23M | 1.29M | 1.27M | 1.24M | 1.24M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |